Drug interactions: Part I.
Gibaldi
M
M
School of Pharmacy, University of Washington, Seattle 98915.
D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology; D002110:Caffeine / Q000494:pharmacology; D002927:Cimetidine / Q000494:pharmacology; D019388:Cytochrome P-450 CYP1A2; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis; D004347:Drug Interactions; D004790:Enzyme Induction; D015725:Fluconazole / Q000494:pharmacology; D005473:Fluoxetine / Q000009:adverse effects / Q000494:pharmacology; D006591:Hexobarbital / Q000494:pharmacology; D006801:Humans; D007654:Ketoconazole / Q000494:pharmacology; D009553:Nimodipine / Q000493:pharmacokinetics; D010088:Oxidoreductases / Q000096:biosynthesis; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D012293:Rifampin / Q000494:pharmacology; D013237:Stereoisomerism; D014859:Warfarin / Q000494:pharmacology; D015215:Zidovudine / Q000037:antagonists & inhibitors / Q000378:metabolism
D000929:Antidepressive Agents, Tricyclic; D065607:Cytochrome P-450 Enzyme Inhibitors; D004364:Pharmaceutical Preparations; D005473:Fluoxetine; D002110:Caffeine; D015215:Zidovudine; D009553:Nimodipine; D014859:Warfarin; D002927:Cimetidine; D015725:Fluconazole; D003577:Cytochrome P-450 Enzyme System; D006591:Hexobarbital; D010088:Oxidoreductases; D019388:Cytochrome P-450 CYP1A2; D007654:Ketoconazole; D012293:Rifampin